Inhibitory effect of silibinin on tumour necrosis factor-alpha and hydrogen peroxide production by human monocytes

Natural Product Research

Volumn 24, Issue 18, 2010, Pages 1747-1757

  Bannwart, C F ^a   Peracoli, J C ^a   Nakaira Takahagi, E ^a   Peracoli M T S ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

flavonoid; hydrogen peroxide; monocytes; silibinin; TNF

Indexed keywords

HYDROGEN PEROXIDE; LIPOPOLYSACCHARIDE; PHORBOL MYRISTATE; SILIBININ; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL ISOLATION; CELL VIABILITY; CHEMICAL STRUCTURE; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG EFFECT; DRUG INHIBITION; HUMAN; HUMAN CELL; MONOCYTE;

ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROGEN PEROXIDE; MILK THISTLE; MOLECULAR STRUCTURE; MONOCYTES; PLANT EXTRACTS; SEEDS; SILYMARIN; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

SILYBUM MARIANUM;

EID: 77953026518     PISSN: 14786419     EISSN: 14786427     Source Type: Journal    
DOI: 10.1080/14786410903314492     Document Type: Article

References (34)

1. Chlopcikova, S., Psotova, J., Miketova, P., & Simanek, V. (2004). Chemoprotective effect of plant phenolics against anthracycline-induced toxicity on rat cardiomyocytes. Phytotherapy Research, 18, 107-110.
2. Comelli, M.C., Mengs, U., Schneider, C, & Prosdocimi, M. (2007). Toward the definition of the mechanism of action of silymarin: Activities related to cellular protection from toxic damage induced by chemotherapy. Integrative Cancer Therapy, 6, 120-129.
3. Dehmlow, C, Murawski, N., & Groot, H. (1996). Scavenging of reactive oxygen species and inhibition of arachidonic acid metabolism by silibinin in human cells. Life Sciences, 58, 1591-1600.
4. Dobrovolskaia, M.A., & Kozlov, S.V. (2005). Inflammation and cancer: When NF-KB amalgamates the perilous partnership. Current Cancer Drug Targets, 5, 325-344.
5. Dooley, D.P., Cox, R.A., Hestilow, K.L., Dolan, M.J., & Magee, D.M. (1994). Cytokine induction in human coccidioidomycosis. Infection and Immunity, 62, 3980-3983.
6. Dorai, T., & Aggarwal, B.B. (2004). Role of chemopreventive agents in cancer therapy. Cancer Letters, 215, 129-140.
7. Dvorak, Z., Kosina, P., Walterova, D., Simanek, V., Bachleda, P., & Ulrichova, J. (2003). Primary cultures of human hepatocytes as a tool in cytotoxicity studies: Cell protection against model toxins by flavonolignans obtained from Silybum marianum. Toxicology Letters, 137, 201-212.
8. Favari, L., & Perez-Alvarez, V. (1997). Comparative effects of colchicine and silymarin on CCl4-chronic liver damage in rats. Archives of Medical Research, 28, 11-17.
9. Ferenci, P., Dragosics, B., Dittrich, H., Frank, H., Benda, L., Lochs, H., et al. (1989). Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. Journal of Hepatology, 9, 105-113.
10. Gallo, D., Giacomelli, S., Ferlini, C, Raspaglio, G., Apollonio, P., Prislei, S., et al. (2003). Antitumour activity of the silybin- phosphatidylcholine complex, IdB 1016, against human ovarian cancer. European Journal of Cancer, 39, 2403-2410.
11. Gazak, R., Walterova, D., & Kren, V. (2007). Silybin and silymarin-new and emerging applications in medicine. Current Medicinal Chemistry, 14, 315-338.
12. Gurley, B.J., Gardner, S.F., Hubbard, M.A., Williams, D.K., Gentry, W.B., Carrier, J., et al. (2004). In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clinical Pharmacology & Therapeutics, 76, 428-440.
13. Han, Y.H., Lou, H.X., Ren, D.M., Sun, L.R., Ma, B., & Ji, M. (2004). Stereoselective metabolism of silybin diastereoisomers in the glucuronidation process. Journal of Pharmaceutical and Biomedical Analysis, 34, 1071-1078.
14. Hoh, C, Boocock, D., Marczylo, T., Singh, R., Berry, D.P., Dennison, A.R., et al. (2006). Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: Silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences. Clinical Cancer Research, 12, 2944-2950.
15. Kang, J.S., Jeon, Y.J., Kim, H.M., Han, S.H., & Yang, K.H. (2002). Inhibition of inducible nitric oxide synthase expression by silymarin in lipopolysaccharide-stimulated macrophages. The Journal of Pharmacology and Experimental Therapeutics, 302, 138-144.
16. Kang, J.S., Jeon, Y.J., Park, S.K., Yang, K.H., & Kim, H.M. (2004). Protection against lipopolysaccharide-induced sepsis and inhibition of interleukin-1beta and prostaglandin E2 synthesis by silymarin. Biochemical Pharmacology, 67, 175-181.
17. Kittur, S., Wilasrusmee, S., Pedersen, W.A., Mattson, M.P., Straube-West, K, Wilasrusmee, C, et al. (2002). Neurotrophic and neuroprotective effects of milk thistle (Silybum marianum) on neurons in culture. Journal of Molecular Neurosciences, 18, 265-269.
18. Kren, V., & Walterova, D. (2005). Silybin and silymarin-New effects and applications. Biomedical Papers, 149, 29-41.
19. Lee, JI, Narayan, M, & Barrett, JS. (2007). Analysis and comparison of active constituents in commercial standardized silymarin extracts by liquid chromatography-electrospray ionization mass spectrometry. Journal of Chromatography B. Analytical Technologies in Biomedical Life Sciences, 845, 95-103.
20. Li, C.Y., Lam, K.W., & Yam, L.T. (1973). Esterases in human leukocytes. Journal of Histochemistry and Cytochemistry, 21, 1-12.
21. Manna, S.K., Mukhopadhyay, A., Van, N.T., & Aggarwal, B.B. (1999). Silymarin suppress TNF induced activation of NF-KB, c-Jun N-terminal kinase, and apoptosis. Journal of Immunology, 163, 6800-6809.
22. Min, K, Yoon, W.K., Kim, S.K., & Kim, B.H. (2007). Immunosuppressive effect of silibinin in experimental autoimmune encephalomyelitis. Archives of Pharmaceutical Research, 30, 1265-1272.
23. Morazzoni, P, Montalbetti, A, Malandrino, S, & Pifferi, G. (1993). Comparative pharmacokinetics of silipide and silymarin in rats. European Journal of Drug Metabolism and Pharmacokinetics, 18, 289-297.
24. Parise-Fortes, M.R., Silva, M.F., Sugizaki, M.F., Defaveri, J., Montenegro, M.R., Soares, A.M., et al. (2000). Experimental paracoccidioidomycosis of the Syrian hamster: Fungicidal activity and production of inflammatory cytokines by macrophages. Medical Mycology, 38, 51-60.
25. Park, E.Y., Ki, S.H., Ko, M.S., Kim, C.W., Lee, M.H., Lee, Y.S., et al. (2005). Garlic oil and DDB, comprised in a pharmaceutical composition for the treatment of patients with viral hepatitis, prevents acute liver injuries potentiated by glutathione deficiency in rats. Chemico-Biological Interaction, 155, 82-96.
26. Peracoli, M.T., Kurokawa, C.S., Calvi, S.A., Mendes, R.P., Pereira, P.C.M., Marques, S.A., et al. (2003). Production of pro-and anti-inflammatory cytokines by monocytes from patients with paracoccidioidomycosis. Microbes and Infection, 5, 413-418.
27. Pradhan, S.C., & Girish, C. (2006). Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian Journal of Medical Research, 124, 491-504.
28. Russo, M., Teixeira, H.C., Marcondes, M.C., & Barbuto, J.A. (1989). Superoxide-independent hydrogen peroxide release by activated macrophages. Brazilian Journal of Medical and Biological Research, 22, 1271-1273.
29. Song, Z., Deaciuc, I., Song, M., Lee, D.Y., Liu, Y., Ji, X., et al. (2006). Silymarin protects against acute ethanol-induced hepatotoxicity in mice. Alcoholism: Clinical and Experimental Research, 30, 407-413.
30. Varga, Z., Czompa, A., Kakuk, G., & Antus, S. (2001). Inhibition of the superoxide anion release and hydrogen peroxide formation in PMNLs by flavonolignans. Phytotherapy Research, 15, 608-612.
31. Wang, M., Grange, L.L., & Tao, J. (1996). Hepatoprotective properties of Silybum marianum herbal preparation on ethanol-induced liver damage. Fitoterapia, 66, 415-420.
32. Wang, M.J., Lin, W.W., Chen, H.L., Chang, Y.H., Ou, H.C., Kuo, J.S., et al. (2002). Silymarin protects dopaminergic neurons against lipopolysaccharide- induced neuro-toxicity by inhibiting microglia activation. European Journal Neurosciences, 16, 2103-2112.
33. Zhang, J.P., Hu, Z.L., Feng, Z.H., Lin, W., Yu, X.B., & Qian, D.H. (1996). Effect of silymarin on mouse liver damage, production and activity of tumor necrosis factor. Yao Xue Xue Bao, 31, 577-580.
34. Zi, X., & Agarwal, R. (1999). Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: Implications for prostate cancer intervention. Proceedings of National Academy of Sciences, 96, 7490-7495.